JPH08510255A - 接合−安定化ポリペプチド組成物 - Google Patents

接合−安定化ポリペプチド組成物

Info

Publication number
JPH08510255A
JPH08510255A JP6525657A JP52565794A JPH08510255A JP H08510255 A JPH08510255 A JP H08510255A JP 6525657 A JP6525657 A JP 6525657A JP 52565794 A JP52565794 A JP 52565794A JP H08510255 A JPH08510255 A JP H08510255A
Authority
JP
Japan
Prior art keywords
peptide
polymer
insulin
group
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP6525657A
Other languages
English (en)
Japanese (ja)
Inventor
エクウライブ．ノッチリ．ヌケム
Original Assignee
プロティン．デリバリー．インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロティン．デリバリー．インコーポレイテッド filed Critical プロティン．デリバリー．インコーポレイテッド
Publication of JPH08510255A publication Critical patent/JPH08510255A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP6525657A 1993-05-10 1994-05-10 接合−安定化ポリペプチド組成物 Withdrawn JPH08510255A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/059,701 1993-05-10
US08/059,701 US5359030A (en) 1993-05-10 1993-05-10 Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
PCT/US1994/005204 WO1994026778A1 (en) 1993-05-10 1994-05-10 Conjugation-stabilized polypeptide compositions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2002260460A Division JP4482267B2 (ja) 1993-05-10 2002-09-05 接合安定化されたポリペプチド組成物
JP2002260459A Division JP2003160598A (ja) 1993-05-10 2002-09-05 接合安定化されたポリペプチド組成物

Publications (1)

Publication Number Publication Date
JPH08510255A true JPH08510255A (ja) 1996-10-29

Family

ID=22024685

Family Applications (4)

Application Number Title Priority Date Filing Date
JP6525657A Withdrawn JPH08510255A (ja) 1993-05-10 1994-05-10 接合−安定化ポリペプチド組成物
JP2002260460A Expired - Lifetime JP4482267B2 (ja) 1993-05-10 2002-09-05 接合安定化されたポリペプチド組成物
JP2002260459A Pending JP2003160598A (ja) 1993-05-10 2002-09-05 接合安定化されたポリペプチド組成物
JP2006202440A Expired - Lifetime JP4012928B2 (ja) 1993-05-10 2006-07-25 接合安定化されたポリペプチド組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2002260460A Expired - Lifetime JP4482267B2 (ja) 1993-05-10 2002-09-05 接合安定化されたポリペプチド組成物
JP2002260459A Pending JP2003160598A (ja) 1993-05-10 2002-09-05 接合安定化されたポリペプチド組成物
JP2006202440A Expired - Lifetime JP4012928B2 (ja) 1993-05-10 2006-07-25 接合安定化されたポリペプチド組成物

Country Status (12)

Country Link
US (2) US5359030A (enExample)
EP (2) EP1264837A1 (enExample)
JP (4) JPH08510255A (enExample)
AT (1) ATE301134T1 (enExample)
AU (1) AU694919B2 (enExample)
CA (1) CA2162366C (enExample)
DE (1) DE69434448T2 (enExample)
DK (1) DK0707596T3 (enExample)
ES (1) ES2247586T3 (enExample)
HK (1) HK1049488A1 (enExample)
IL (1) IL109619A (enExample)
WO (1) WO1994026778A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001048052A1 (en) 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
JP2003502364A (ja) * 1999-06-19 2003-01-21 ノベックス・コーポレイション 加水分解型親油性成分を有する両親媒性薬物−オリゴマー結合体およびその製造法および使用法
JP2003206236A (ja) * 1993-05-10 2003-07-22 Nobex Corp 接合安定化されたポリペプチド組成物
JP4758608B2 (ja) * 2001-11-07 2011-08-31 ネクター セラピューティックス 分枝ポリマーおよびそれらの結合体
JP2015514108A (ja) * 2012-04-05 2015-05-18 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
US12453777B2 (en) 2019-03-20 2025-10-28 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor

Families Citing this family (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
DE4437502A1 (de) * 1993-12-02 1995-06-08 Basf Ag Hirudin-Konjugate aus Hirudin und lipophilen Verbindungen
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
RU2066551C1 (ru) * 1994-03-23 1996-09-20 Институт нефтехимического синтеза РАН Способ получения инсулинсодержащих полимерных гидрогелей
AU2455295A (en) * 1994-05-20 1995-12-18 Hisamitsu Pharmaceutical Co., Inc. Protein or polypeptide, process for producing the same, and intermediate compound tehrefor
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6004583A (en) * 1995-03-22 1999-12-21 Orex Pharmaceutical Development Corp. Protein-containing polymer composition for oral administration
CA2279669A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EP0918543B1 (en) * 1996-08-02 2004-04-21 Orex Pharmaceutical Development Corp. Polymer composition for oral administration of peptides and proteins
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
DE69713517D1 (de) 1996-10-15 2002-07-25 Medical Analysis Systems Inc Verfahren zur Stabilisierung von Troponin I (CTnI) durch Konjugation mit einem activen Polymer
US6132712A (en) * 1996-12-11 2000-10-17 A. Glenn Braswell Superoxide dismutase stabilized with fragments of casein and pharmaceutical compositions incorporating same
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
WO1998049198A1 (en) * 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US20040009166A1 (en) * 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
CA2263795C (en) * 1997-06-06 2008-02-19 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US6165458A (en) * 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
AU2610899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
KR19990085365A (ko) * 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
CN1170543C (zh) * 1998-06-08 2004-10-13 弗·哈夫曼-拉罗切有限公司 PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
EA004789B9 (ru) * 1998-10-16 2017-05-31 Байоджен, Инк. Полимерные конъюгаты бета-1а-интерферона и их использование
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
WO2000075105A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
US6209490B1 (en) * 1999-06-17 2001-04-03 Gary J. Schwede Living quarters container for cats or ferrets
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
ES2275561T3 (es) * 1999-10-04 2007-06-16 Nektar Therapeutics Al, Corporation Neuropeptidos estabilizados por polimeros.
RU2155602C1 (ru) * 1999-11-30 2000-09-10 Оао "Куантум Сатис" Инсулинсодержащее лекарственное средство для перорального применения и способ его получения
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
KR100890125B1 (ko) 2000-02-24 2009-03-24 일라이 릴리 앤드 캄파니 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
AU2001268228A1 (en) 2000-06-08 2001-12-17 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
AU2001271491A1 (en) * 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
US7105154B2 (en) * 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
US20030219405A1 (en) * 2002-01-16 2003-11-27 Yoshihiro Sokawa Oral administration of interferon-tau
SK2772003A3 (en) * 2000-09-08 2003-10-07 Gryphon Therapeutics Inc Synthetic erythropoiesis stimulating proteins
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6538104B2 (en) * 2001-04-27 2003-03-25 Medical Analysis Systems, Inc. Stabilization of cardiac troponin I subunits and complexes
WO2002089830A1 (en) * 2001-05-04 2002-11-14 North Carolina State University Polymer conjugates of insecticidal peptides or nucleic acids and methods of use thereof
US20030108585A1 (en) * 2001-05-04 2003-06-12 Roe R. Michael Polymer conjugates of insecticidal peptides or nucleic acids or insecticides and methods of use thereof
AR033903A1 (es) * 2001-05-21 2004-01-07 Inhale Therapeutic Syst Una composicion de insulina modificada quimicamente para la administracion pulmonar
EP1405871A4 (en) * 2001-05-30 2004-11-17 Mitsubishi Kagaku Iatron Inc METHOD FOR BINDING A SUBSTANCE TO BE INCORPORATED AT A POLYMER END
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7008650B2 (en) * 2001-08-09 2006-03-07 Lam Paul Y S Compositions for the treatment of acquired immunodeficiency disease
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
CA2457885A1 (en) * 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
WO2003022996A2 (en) * 2001-09-07 2003-03-20 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
PL370889A1 (en) * 2001-12-20 2005-05-30 Femmepharma, Inc. Vaginal delivery of drugs
CA2473526C (en) 2002-01-18 2013-10-22 Biogen Idec Ma Inc. Polyalkylene polymer compounds and uses thereof
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
WO2003099830A2 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions, methods of preparation and use
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
HK1079995A1 (zh) * 2002-09-05 2006-04-21 The General Hospital Corporation 修饰的脱唾液酸-干扰素系及其应用
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
DE60331584D1 (de) * 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1578437A4 (en) * 2002-12-27 2006-08-09 Diobex Inc COMPOSITIONS AND METHODS FOR PREVENTING AND REDUCING INSULIN-INDUCED HYPOGLYCEMIA
AU2004203700B2 (en) * 2003-01-02 2007-06-21 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US7074755B2 (en) * 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
KR20060032140A (ko) * 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
US20060078560A1 (en) * 2003-06-23 2006-04-13 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
BRPI0412265A (pt) * 2003-07-23 2006-09-05 Novartis Ag uso de calcitonina em osteoartrite
KR101152470B1 (ko) 2003-08-13 2012-06-01 바이오콘 리미티드 치료제용 마이크로-입자 지방산 염 고형 투약 제형
CN1901934B (zh) * 2003-12-19 2013-09-11 弗·哈夫曼-拉罗切有限公司 促红细胞生成素在治疗慢性炎症性肠病中铁分布紊乱中的用途
US20050136121A1 (en) * 2003-12-22 2005-06-23 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
SE0401942D0 (sv) * 2004-07-28 2004-07-28 Lipopeptide Ab New antimicrobial peptide complexes
WO2005115477A2 (en) * 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
PT1773878E (pt) * 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
EP2248531A1 (en) 2004-08-03 2010-11-10 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
TW200612993A (en) * 2004-10-08 2006-05-01 Alza Corp Lipopolymer conjugates
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
WO2006079641A2 (en) * 2005-01-27 2006-08-03 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
ES2490243T3 (es) * 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
KR101225679B1 (ko) * 2005-07-08 2013-01-23 바이오콘 리미티드 인슐린 복합체의 제조
ATE524509T1 (de) 2005-07-18 2011-09-15 Nektar Therapeutics Verzweigte funktionalisierte polymere unter verwendung von verzweigten polyolen als kernen
JP5047978B2 (ja) * 2005-10-13 2012-10-10 バイオコン・リミテッド インスリン複合体の調製のための方法
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
RU2469709C2 (ru) 2005-11-17 2012-12-20 Новартис Аг Фармацевтическая композиция
GB0604187D0 (en) * 2006-03-02 2006-04-12 Fusion Antibodies Ltd Peptide and uses thereof
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
KR101434612B1 (ko) 2006-03-30 2014-08-26 팔라틴 테크놀로지스 인코포레이티드 사이클릭 나트륨 이뇨 펩타이드 구조물
EP2004633A4 (en) * 2006-03-30 2009-08-26 Palatin Technologies Inc LINEAR NATRIURETIC PEPTIDE CONSTRUCTS
MX2008014061A (es) * 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
BRPI0712559A2 (pt) 2006-05-26 2012-11-20 Amylin Pharmaceuticals Inc composiÇÕes e mÉtodos para o tratamento de insuficiÊncia cardÍaca congestiva
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
WO2007149594A2 (en) * 2006-06-23 2007-12-27 Quintessence Biosciences, Inc. Modified ribonucleases
US8298801B2 (en) 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
EP2066337A2 (en) * 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
PL2074141T3 (pl) * 2006-09-22 2017-02-28 Novo Nordisk A/S Analogi insuliny oporne na proteazę
WO2008049011A2 (en) * 2006-10-18 2008-04-24 Research Development Foundation Alpha-msh therapies for treatment of autoimmune disease
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
SG177953A1 (en) * 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
JP5496082B2 (ja) * 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
MX2009012789A (es) * 2007-06-01 2009-12-10 Novo Nordisk As Composiciones farmaceuticas no acuosas estables.
US7776827B2 (en) * 2007-07-27 2010-08-17 Immuneregen Biosciences, Inc. Method of using substance P analogs for treatment amelioration of myelodysplastic syndrome
US8697062B2 (en) * 2007-10-08 2014-04-15 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapeutics
NZ585135A (en) 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
US8981047B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Glucagon antagonists
CA2702289A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
WO2009112583A2 (en) * 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
BRPI0915282A2 (pt) * 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
EP2307037A4 (en) * 2008-06-17 2011-08-03 Univ Indiana Res & Tech Corp GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS
CA2728284C (en) 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
CN102112157B (zh) * 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
CN102227443B (zh) 2008-10-01 2014-05-14 昆特森斯生物科学公司 治疗性核糖核酸酶
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
AR074811A1 (es) 2008-12-19 2011-02-16 Univ Indiana Res & Tech Corp Profarmaco de peptido de la superfamilia de glucagon basados en amida
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
EP2389389B1 (en) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stable growth hormone compounds
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CN102369018B (zh) 2009-03-12 2016-08-03 关键生物科学有限公司 糖尿病和代谢综合征的治疗
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
HUP0900482A2 (en) 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011045232A2 (en) * 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
SG181769A1 (en) 2009-12-21 2012-07-30 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
SI2525834T1 (sl) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
CN102834108A (zh) 2010-01-27 2012-12-19 印第安纳大学研究及科技有限公司 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
EP2585102B1 (en) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
RU2437675C1 (ru) * 2010-10-11 2011-12-27 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") Гемостимулирующее средство
WO2012088116A2 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
CN103415621A (zh) 2011-01-14 2013-11-27 雷德伍德生物科技股份有限公司 醛标记免疫球蛋白多肽及其使用方法
PH12013502671A1 (en) 2011-06-22 2022-04-08 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
EP2723766A4 (en) 2011-06-22 2015-05-20 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
WO2013033476A1 (en) * 2011-08-30 2013-03-07 Quanta Biodesign, Ltd. Branched discrette peg constructs
CN103998052B (zh) 2011-11-02 2016-08-17 关键生物科学有限公司 用于治疗疾病和紊乱的肽类似物
EP2773365B1 (en) 2011-11-02 2016-07-20 KeyBioscience AG Peptide analogs for treating diseases and disorders
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
WO2013096386A1 (en) 2011-12-20 2013-06-27 Indiana University Research And Technology Corporation Ctp-based insulin analogs for treatment of diabetes
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
WO2014179344A1 (en) * 2013-04-30 2014-11-06 Massachusetts Institute Of Technology Injectable nano-network gels for diabetes treatment
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
CN105636979B (zh) 2013-10-07 2020-01-10 诺和诺德股份有限公司 胰岛素类似物的新衍生物
JP6639389B2 (ja) 2013-11-14 2020-02-05 キーバイオサイエンス・アクチエンゲゼルシャフト 疾患および障害を処置するためのカルシトニン模倣体
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
TW201625678A (zh) * 2014-11-21 2016-07-16 美國芝加哥州立大學 合成肽
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CA2981501A1 (en) 2015-06-04 2016-12-08 Antriabio, Inc. Amine pegylation methods for the preparation of site-specific protein conjugates
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC ANTIBODY CONJUGATES AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20180169190A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
WO2018136779A2 (en) 2017-01-19 2018-07-26 The University Of Chicago OXALOBACTER FORMIGENES(Of)-DERIVED FACTORS FOR THE TREATMENT OF TREATMENT/PREVENTION OF EXCESS OXALATE LEVELS
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
EP3625247A4 (en) 2017-05-16 2021-03-24 The University of Chicago COMPOSITIONS AND METHODS FOR TREATMENT AND / OR PREVENTION OF PATHOGENIC FUNGAL INFECTIONS AND MAINTAINING MICROBIOMAL COMENSALISM
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
US12016899B2 (en) 2018-07-18 2024-06-25 The University Of Chicago Compositions comprising Sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
KR20240171428A (ko) 2023-05-30 2024-12-09 (주)네오비젼 당뇨병 치료를 위한 약물 방출 제어가 가능한 약물 전달용 콘택트렌즈

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0395200A (ja) * 1989-05-27 1991-04-19 Sumitomo Pharmaceut Co Ltd ポリエチレングリコール誘導体を得る製造方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US4044196A (en) * 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4094196A (en) * 1977-02-25 1978-06-13 Waters Associates, Inc. Sample injection with automatic cleaning of sampling conduit
DE2930542A1 (de) * 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
GB2107185A (en) * 1981-10-07 1983-04-27 John Kenneth Mcmullen Insulin formulations containing surface-active agents
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
US4585754A (en) * 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4849405A (en) * 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
JPS62252800A (ja) * 1986-03-27 1987-11-04 Bitamin Kenkyusho:Kk 化学修飾タンパク質の製法
JPS63152393A (ja) * 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
CA1308377C (en) * 1987-08-21 1992-10-06 Henry Berger, Jr. Complex of polyethyleneglycol and tissue plasminogen activator
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IT1229514B (it) * 1989-01-30 1991-09-03 Farmhispania S A A Montme Glicoconiugati anfifilici sintetici per impiego neurologico.
ATE181732T1 (de) * 1989-04-19 1999-07-15 Novo Nordisk As Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden
US5108568A (en) * 1989-07-07 1992-04-28 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0395200A (ja) * 1989-05-27 1991-04-19 Sumitomo Pharmaceut Co Ltd ポリエチレングリコール誘導体を得る製造方法

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003206236A (ja) * 1993-05-10 2003-07-22 Nobex Corp 接合安定化されたポリペプチド組成物
JP2003502364A (ja) * 1999-06-19 2003-01-21 ノベックス・コーポレイション 加水分解型親油性成分を有する両親媒性薬物−オリゴマー結合体およびその製造法および使用法
WO2001048052A1 (en) 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
JP4593048B2 (ja) * 1999-12-24 2010-12-08 協和発酵キリン株式会社 分岐型ポリアルキレングリコール類
JP4758608B2 (ja) * 2001-11-07 2011-08-31 ネクター セラピューティックス 分枝ポリマーおよびそれらの結合体
JP2015514108A (ja) * 2012-04-05 2015-05-18 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
JP2017165739A (ja) * 2012-04-05 2017-09-21 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
JP2020143165A (ja) * 2012-04-05 2020-09-10 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
JP2022191408A (ja) * 2012-04-05 2022-12-27 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
US12303566B2 (en) 2012-04-05 2025-05-20 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
US12453777B2 (en) 2019-03-20 2025-10-28 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor

Also Published As

Publication number Publication date
JP2003206236A (ja) 2003-07-22
IL109619A0 (en) 1994-08-26
DE69434448T2 (de) 2006-06-08
US5438040A (en) 1995-08-01
JP2006348039A (ja) 2006-12-28
US5359030A (en) 1994-10-25
HK1049488A1 (en) 2003-05-16
EP0707596B1 (en) 2005-08-03
AU694919B2 (en) 1998-08-06
EP0707596A4 (en) 1997-11-12
WO1994026778A1 (en) 1994-11-24
DE69434448D1 (de) 2005-09-08
CA2162366C (en) 2009-10-27
JP4012928B2 (ja) 2007-11-28
EP1264837A1 (en) 2002-12-11
IL109619A (en) 2000-12-06
ES2247586T3 (es) 2006-03-01
EP0707596A1 (en) 1996-04-24
JP4482267B2 (ja) 2010-06-16
AU6946694A (en) 1994-12-12
ATE301134T1 (de) 2005-08-15
JP2003160598A (ja) 2003-06-03
DK0707596T3 (da) 2005-12-12
CA2162366A1 (en) 1994-11-24

Similar Documents

Publication Publication Date Title
JPH08510255A (ja) 接合−安定化ポリペプチド組成物
AU698944B2 (en) Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
US20220133898A1 (en) Derivatisation of Insulin with Polysaccharides
US6191105B1 (en) Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US6323311B1 (en) Synthesis of insulin derivatives
US8784849B2 (en) Hydroxyapatite-targeting poly(ethylene glycol) and related polymers
JP2006321808A (ja) 化学的に修飾されたヒト成長ホルモンコンジュゲート
JP2003516366A (ja) 両親媒性ポリマーとこれを含有するポリペプチドコンジュゲート
US20040127417A1 (en) N-terminally monopegylated human growth hormone conjugates and process for their preparation
KR101104574B1 (ko) 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
CN1080575C (zh) 结合稳定的多肽组合物、其治疗、诊断制剂及其制备和使用方法
US20050181976A1 (en) Amphiphilic oligomers
MXPA98000883A (en) Compositions of therapeutic agent stabilized by conjugation, supply and formulations of diagnost

Legal Events

Date Code Title Description
A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20040205

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20040120